• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

因子 V 和 VIII 辅因子激活的分子基础。

The molecular basis of factor V and VIII procofactor activation.

机构信息

Department of Pediatrics, Division of Hematology, The Children's Hospital of Philadelphia and The University of Pennsylvania, School of Medicine, Philadelphia, PA, USA.

出版信息

J Thromb Haemost. 2009 Dec;7(12):1951-61. doi: 10.1111/j.1538-7836.2009.03622.x. Epub 2009 Sep 18.

DOI:10.1111/j.1538-7836.2009.03622.x
PMID:19765210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2993324/
Abstract

Activation of precursor proteins by specific and limited proteolysis is a hallmark of the hemostatic process. The homologous coagulation factors (F)V and FVIII circulate in an inactive, quiescent state in blood. In this so-called procofactor state, these proteins have little, if any procoagulant activity and do not participate to any significant degree in their respective macromolecular enzymatic complexes. Thrombin is considered a key physiological activator, cleaving select peptide bonds in FV and FVIII which ultimately leads to appropriate structural changes that impart cofactor function. As the active cofactors (FVa and FVIIIa) have an enormous impact on thrombin and FXa generation, maintaining FV and FVIII as inactive procofactors undoubtedly plays an important regulatory role that has likely evolved to maintain normal hemostasis. Over the past three decades there has been widespread interest in studying the proteolytic events that lead to the activation of these proteins. While a great deal has been learned, mechanistic explanations as to how bond cleavage facilitates conversion to the active cofactor species remain incompletely understood. However, recent advances have been made detailing how thrombin recognizes FV and FVIII and also how the FV B-domain plays a dominant role in maintaining the procofactor state. Here we review our current understanding of the molecular process of procofactor activation with a particular emphasis on FV.

摘要

特异性和有限性蛋白水解作用激活前体蛋白是止血过程的一个标志。同源凝血因子(F)V 和 FVIII 在血液中以无活性、静止状态循环。在这种所谓的前体因子状态下,这些蛋白质几乎没有,如果有的话,促凝活性,并且不会以任何显著程度参与各自的大分子酶复合物。凝血酶被认为是一种关键的生理激活剂,它在 FV 和 FVIII 中切割特定的肽键,最终导致适当的结构变化,赋予辅助因子功能。由于活性辅因子(FVa 和 FVIIIa)对凝血酶和 FXa 的生成有巨大影响,将 FV 和 FVIII 保持为无活性的前体因子无疑发挥了重要的调节作用,这种作用可能是为了维持正常的止血而进化而来的。在过去的三十年中,人们对导致这些蛋白质激活的蛋白水解事件产生了广泛的兴趣。虽然已经学到了很多,但对于键裂解如何促进转化为活性辅因子的机制解释仍不完全清楚。然而,最近的进展详细描述了凝血酶如何识别 FV 和 FVIII,以及 FV B 结构域如何在维持前体因子状态中发挥主导作用。在这里,我们重点讨论 FV,回顾我们对前体因子激活的分子过程的现有认识。

相似文献

1
The molecular basis of factor V and VIII procofactor activation.因子 V 和 VIII 辅因子激活的分子基础。
J Thromb Haemost. 2009 Dec;7(12):1951-61. doi: 10.1111/j.1538-7836.2009.03622.x. Epub 2009 Sep 18.
2
Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.血液凝固因子V和VIII:辅凝血因子激活的分子机制
J Coagul Disord. 2010 Jul 1;2(2):19-27.
3
Coagulation procofactor activation by factor XIa.凝血因子 XIa 对凝血酶原激活物的激活作用。
J Thromb Haemost. 2010 Jul;8(7):1532-9. doi: 10.1111/j.1538-7836.2010.03899.x. Epub 2010 May 4.
4
A bipartite autoinhibitory region within the B-domain suppresses function in factor V.因子 V 中 B 结构域内的二联体自身抑制区抑制其功能。
J Biol Chem. 2012 Jul 27;287(31):26342-51. doi: 10.1074/jbc.M112.377168. Epub 2012 Jun 15.
5
Factor VIII and Factor V Membrane Bound Complexes.VIII 因子和 V 因子膜结合复合物。
Subcell Biochem. 2021;96:153-175. doi: 10.1007/978-3-030-58971-4_2.
6
Factor V C2 domain contains a major thrombin-binding site responsible for thrombin-catalyzed factor V activation.凝血因子V的C2结构域包含一个主要的凝血酶结合位点,该位点负责凝血酶催化的凝血因子V激活。
J Thromb Haemost. 2006 Jun;4(6):1354-60. doi: 10.1111/j.1538-7836.2006.01957.x.
7
The structural integrity of anion binding exosite I of thrombin is required and sufficient for timely cleavage and activation of factor V and factor VIII.凝血酶阴离子结合外位点I的结构完整性对于因子V和因子VIII的及时裂解和激活是必需且充分的。
J Biol Chem. 2006 Jul 7;281(27):18569-80. doi: 10.1074/jbc.M600752200. Epub 2006 Apr 19.
8
The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V.凝血因子V的B结构域的C末端区域对于凝血因子V的抗凝活性至关重要。
J Biol Chem. 1998 Jun 26;273(26):16140-5. doi: 10.1074/jbc.273.26.16140.
9
Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.通过分子建模对人凝血因子V的A结构域进行结构研究。
Protein Sci. 1998 Jun;7(6):1317-25. doi: 10.1002/pro.5560070607.
10
Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.TFPIα 对因子 V 和因子 V 短片段的调节:B 结构域蛋白水解与结合的关系。
J Biol Chem. 2021 Jan-Jun;296:100234. doi: 10.1074/jbc.RA120.016341. Epub 2021 Jan 7.

引用本文的文献

1
Basic regions of factor V and tissue factor pathway inhibitor mediate heavy chain and acidic region interactions on factor V revealed by tethered chemical cleavage.通过连接化学切割揭示的凝血因子V和组织因子途径抑制剂的基本区域介导凝血因子V重链与酸性区域的相互作用。
J Thromb Haemost. 2025 Aug;23(8):2449-2460. doi: 10.1016/j.jtha.2025.04.028. Epub 2025 May 12.
2
Atomistic Mechanism of Lipid Membrane Binding for Blood Coagulation Factor VIII with Molecular Dynamics Simulations on a Microsecond Time Scale.基于微秒时间尺度分子动力学模拟的凝血因子VIII脂质膜结合的原子机制
J Phys Chem B. 2025 Feb 6;129(5):1486-1498. doi: 10.1021/acs.jpcb.4c06575. Epub 2025 Jan 22.
3

本文引用的文献

1
Parahaemophilia; haemorrhagic diathesis due to absence of a previously unknown clotting factor.副血友病;因缺乏一种先前未知的凝血因子而导致的出血素质。
Lancet. 1947 Apr 5;1(6449):446-8.
2
Venom factor V from the common brown snake escapes hemostatic regulation through procoagulant adaptations.来自普通棕蛇的毒液因子V通过促凝血适应性逃避止血调节。
Blood. 2009 Jul 16;114(3):686-92. doi: 10.1182/blood-2009-02-202663. Epub 2009 Apr 13.
3
Cleavage at Arg-1689 influences heavy chain cleavages during thrombin-catalyzed activation of factor VIII.
Genome-Wide Search for Nonadditive Allele Effects Identifies as Involved in the Variability of Factor V Activity.
全基因组搜索非加性等位基因效应鉴定为参与因子 V 活性的变异性。
J Am Heart Assoc. 2024 Nov 5;13(21):e034943. doi: 10.1161/JAHA.124.034943. Epub 2024 Oct 18.
4
The Prothrombin-Prothrombinase Interaction.凝血酶原-凝血酶酶促复合物的相互作用。
Subcell Biochem. 2024;104:409-423. doi: 10.1007/978-3-031-58843-3_15.
5
Variant spectrum of and in hemophilia patients from southern China and 26 novel variants.中国南方血友病患者中[具体基因名称]的变异谱及26种新变异
Front Genet. 2023 Dec 22;14:1254265. doi: 10.3389/fgene.2023.1254265. eCollection 2023.
6
evidence of Remdesivir action in blood coagulation cascade modulation in COVID-19 treatment.瑞德西韦在新冠病毒疾病治疗中调节凝血级联反应的作用证据。
World J Biol Chem. 2023 Jul 27;14(4):72-83. doi: 10.4331/wjbc.v14.i4.72.
7
Cryo-EM structure of coagulation factor V short.凝血因子 V 短链的冷冻电镜结构。
Blood. 2023 Jun 29;141(26):3215-3225. doi: 10.1182/blood.2022019486.
8
Cryo-EM structures of coagulation factors.凝血因子的冷冻电镜结构
Res Pract Thromb Haemost. 2022 Nov 2;6(7):e12830. doi: 10.1002/rth2.12830. eCollection 2022 Oct.
9
Translational readthrough at nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association.翻译:因子 VIII B 结构域无义变异的翻译通读导致残留表达,并降低抑制剂的结合。
Haematologica. 2023 Feb 1;108(2):472-482. doi: 10.3324/haematol.2022.281279.
10
A Novel Phenotype of the Factor 5 Gene Mutation (Homozygote Met1736Val and Heterozygote Asp68His) Is Associated With Moderate Factor V Deficiency.因子Ⅴ基因突变(纯合子Met1736Val和杂合子Asp68His)的一种新表型与中度因子Ⅴ缺乏相关。
Front Med (Lausanne). 2022 Jun 9;9:870269. doi: 10.3389/fmed.2022.870269. eCollection 2022.
在凝血酶催化的因子VIII激活过程中,精氨酸-1689处的切割影响重链切割。
J Biol Chem. 2009 Apr 24;284(17):11080-9. doi: 10.1074/jbc.M900234200. Epub 2009 Feb 24.
4
Acidic residues C-terminal to the A2 domain facilitate thrombin-catalyzed activation of factor VIII.A2结构域C端的酸性残基有助于凝血酶催化的凝血因子VIII激活。
Biochemistry. 2008 Aug 19;47(33):8786-95. doi: 10.1021/bi8007824. Epub 2008 Jul 22.
5
Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.人凝血因子VIII的晶体结构:对凝血因子IXa-凝血因子VIIIa复合物形成的影响
Structure. 2008 Apr;16(4):597-606. doi: 10.1016/j.str.2008.03.001.
6
A unique function for LRP-1: a component of a two-receptor system mediating specific endocytosis of plasma-derived factor V by megakaryocytes.低密度脂蛋白受体相关蛋白-1(LRP-1)的独特功能:双受体系统的一个组成部分,介导巨核细胞对血浆源性因子V的特异性内吞作用。
J Thromb Haemost. 2008 Apr;6(4):638-44. doi: 10.1111/j.1538-7836.2008.02894.x. Epub 2008 Jan 9.
7
The tertiary structure and domain organization of coagulation factor VIII.凝血因子VIII的三级结构和结构域组织
Blood. 2008 Feb 1;111(3):1240-7. doi: 10.1182/blood-2007-08-109918. Epub 2007 Oct 26.
8
The role of thrombin exosites I and II in the activation of human coagulation factor V.凝血酶外位点I和II在人凝血因子V激活中的作用。
J Biol Chem. 2007 Nov 23;282(47):33915-24. doi: 10.1074/jbc.M701123200. Epub 2007 Sep 18.
9
Coagulation factor V and thrombophilia: background and mechanisms.凝血因子V与血栓形成倾向:背景与机制
Thromb Haemost. 2007 Sep;98(3):530-42.
10
Plasma Accelerator Factor and Purified Prothrombin Activation.血浆促凝因子与纯化凝血酶原激活
Science. 1947 Jul 11;106(2741):41-2. doi: 10.1126/science.106.2741.41-a.